No statistical survival advantage was observed with EGFR nor with PDGFRA transcripts despite the distinct differences at mRNA and protein levels between IDH-wildtype and IDH-mutant gliomas (Figure S3A). This evidence concerns the gene PDGFRA and central nervous system cancer.